Blog
Drug Target Encyclopedia Series (10) — SLAMF7
Release Time：
2025-12-05 13:26
SLAMF7 is an immunomodulatory receptor primarily expressed on natural killer (NK) cells, plasma cells, and subsets of T and B cells. Unlike many targets, SLAMF7 is not widely expressed in healthy tissues, making it an attractive candidate for immune-oncology therapies.
SLAMF7 is overexpressed in:
• Multiple myeloma
• Chronic lymphocytic leukemia (CLL)
• Diffuse large B-cell lymphoma (DLBCL)
• Other plasma cell dyscrasias
Targeting SLAMF7 in oncology:
- Monoclonal antibodies – Elotuzumab (FDA-approved) enhances NK cell-mediated cytotoxicity in multiple myeloma.
- Bispecific antibodies – SLAMF7/CD3 formats are under development to engage T cells in tumor killing.
- CAR-T cell therapy – SLAMF7-CAR-T is being explored in early-phase trials, offering potential for relapsed/refractory myeloma.
- Immunocytokines – Engineered cytokines targeting SLAMF7 to improve local immune activation.
Challenges include fratricide in CAR-T cells (due to SLAMF7 expression on T cells), potential NK cell exhaustion, and immune escape mechanisms in heavily treated patients.
Current research focuses on CRISPR-based editing to eliminate SLAMF7 from T cells, improving CAR construct design, and combination with checkpoint blockade to enhance efficacy.
Need SLAMF7 tools for your research?
Fill out the form below, or visit the link: to browse the complete list of available in-stock products.
E-mail：support@levostar.com
USA
16192 Coastal Hwy，Lewes, DE 19958
TEL：619-537-9202
China
A3-502 No.328, Xinghu Street, Suzhou Industrial Park, Suzhou, Jiangsu, China 215123
TEL：0512-62888898